Analysts’ Opinions Are Mixed on These Healthcare Stocks: BioCryst (BCRX), Arcus Biosciences (RCUS) and Amicus (FOLD)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioCryst (BCRX – Research Report), Arcus Biosciences (RCUS – Research Report) and Amicus (FOLD – Research Report).
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
BioCryst (BCRX)
Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on BioCryst on December 12 and set a price target of $15.00. The company’s shares closed last Friday at $7.57.
According to TipRanks.com, Ahmad is a 4-star analyst with an average return of
BioCryst has an analyst consensus of Strong Buy, with a price target consensus of $19.27, representing a 146.4% upside. In a report issued on December 12, Wedbush also maintained a Buy rating on the stock with a $21.00 price target.
See today’s best-performing stocks on TipRanks >>
Arcus Biosciences (RCUS)
Bank of America Securities analyst Jason Zemansky maintained a Hold rating on Arcus Biosciences on December 12 and set a price target of $26.00. The company’s shares closed last Friday at $21.53.
According to TipRanks.com, Zemansky is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arcus Biosciences with a $27.78 average price target, implying a 31.3% upside from current levels. In a report issued on December 7, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $27.00 price target.
Amicus (FOLD)
In a report issued on December 12, Maxwell Skor from Morgan Stanley maintained a Buy rating on Amicus, with a price target of $12.00. The company’s shares closed last Friday at $10.55.
According to TipRanks.com, Skor is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Amicus with a $15.88 average price target.
